Antimicrobial Susceptibility Testing & Minimal Inhibitory Concentration
Unlike today’s current technologies and testing methods used in the AST space, ImpeDx m-EIS technology can conduct AST testing in hours opposed to days. Moreover, our technology can often be applied direct-on-sample, or after only minimal sample preparation.
Urinary Tract Infections
Urinary tract infections and urine specimens can make up as much as 60% of all daily collected clinical samples in hospitals. These infections usually are not life threatening, but impact quality of life and can become more severe in immunocompromised patients leading to significant complications during a patients stay in hospital.
STDs and Gonorrhea
ImpeDx continues to expand our offering working towards including tests suitable for STDs, in particular focusing on Gonorrhea testing in partnership with the US Centers for Disease Control (CDC). ImpeDx is a proud member of the CDCs team and efforts to target STDs like Gonorrhea that continue to demonstrate antimicrobial resistance at alarming rates of increase since 2016.
Blood and Sepsis
Today, sepsis is the leading cause of death in hospitals in developed countries. AST testing on positive blood cultures typically requires precious time that patients don’t have. We are working to bring this process in line with rapid identification technologies in order to avoid time patients spend in intensive care units and to save lives. To learn more click here.
Tuberculosis and NTMs
Tuberculosis and non-Tuberculosis Mycobacterial infections continue to be a top concern globally. The World Health Organization continues its focus of attempting to eradicate TB - setting a goal to eliminate TB as a public health problem by 2050. However, the incidence of resistant Tuberculosis continues to rise in some areas of the globe. These bacterial infections and those that are multidrug-resistant (MDR) and extensively drug-resistant (XDR) pose a threat to developed world populations as well. Click here to learn more.